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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Romanian language. 
The reading comprehension of the questionnaire was tested in 15 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 310 JIA patients (11.9% systemic, 21.6% oligoarticular, 31.9% RF-negative polyarthritis, 
34.6% other categories) and 100 healthy children, were enrolled in six centres. The JAMAR components discriminated well 
healthy subjects from JIA patients except for the health-related quality of life psychosocial health subscales. All JAMAR 
components revealed good psychometric performances. In conclusion, the Romanian version of the JAMAR is a valid tool 
for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Romanian parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Romanian language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from April 2011 to 
March 2013. Children were recruited after Ethics Committee 
approval and consent from at least one parent.
The JAMAR
The JAMAR (1) includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients. For the Romanian version of JAMAR, the 
probe technique was assessed by a probe sample of 15 JIA 
parents and patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
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validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Romanian parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Romanian JAMAR was fully cross-culturally adapted 
from the standard English version with two forward and two 
backward translations with a concordance for 116/123 lines 
(94.3%) for the parent version and 107/120 lines (89.2%) for 
the child version.
All 123 lines of the parent version of the JAMAR were 
understood by at least 80% of the 15 parents tested (median 
100%; range 87–100%). All the 120 lines of the patient ver-
sion of the JAMAR were understood by at least 80% of the 
children (median 100%; range 100–100%). Both versions 
of the JAMAR were unmodified after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 311 JIA patients and 100 healthy children (total 
of 411 subjects), were enrolled at six paediatric rheumatol-
ogy centres. One patient did not give the consent to use his/
her data.
In the remaining 310 JIA subjects, the JIA categories 
were 11.9% with systemic arthritis, 21.6% with oligoarthri-
tis, 31.9% with RF-negative polyarthritis, 9.4% with RF-
positive polyarthritis, 1.9% with psoriatic arthritis, 20% with 
enthesitis-related arthritis and 3.2% with undifferentiated 
arthritis (Table 1).
A total of 390/410 (95.1%) subjects had the parent ver-
sion of the JAMAR completed by a parent (290 from parents 
of JIA patients and 100 from parents of healthy children). 
The JAMAR was completed by 333/390 (85.4%) mothers 
and 57/390 (14.6%) fathers. The child version of the JAMAR 
was completed by 364/410 (88.8%) children aged five or 
older. In addition, patients younger than 7 years, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in psychosocial quality of life items.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 0.7% (0–2.8%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices were used for PF items 6 and 11.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL items 1, 8 and 9 (data not shown). The 
median number of items marked as not applicable was 0% 
(0–7%) for the PF and 3% (0–16%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 78.3% (56.9–88.3%) for the 
PF items, 52.1% (27.2–66.9%) for the HRQoL-PhH items, 
and 48.6% (37.9–71.0%) for the HRQoL-PsH items. The 
median ceiling effect was 1% (0–7.6%) for the PF items, 
10.3% (5.2–12.4%) for the HRQoL-PhH items, and 5.2% 
(1–8.6%) for the HRQoL-PsH items. The median floor effect 
was 30% for the pain VAS, 30.3% for the disease activity 
VAS and 29% for the well-being VAS. The median ceiling 
effect was 2.1% for the pain VAS, 1% for the disease activity 
VAS and 1.4% for the well-being VAS.
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 310 JIA patients
Data related to the JAMAR refers to the 290 JIA patients and to the 100 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS Visual Analogue 
Scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic 
(N = 37)
Oligoarthritis 
(N = 67)
RF− pol-
yarthritis 
(N = 99)
RF+ poly-
arthritis 
(N = 29)
Psoriatic 
arthritis 
(N = 6)
Enthesitis-
related arthri-
tis (N = 62)
Undifferenti-
ated arthritis 
(N = 10)
All JIA 
patients 
(N = 310)
Healthy 
(N = 100)
Female 16 (43.2%) 46 (68.7%) 63 (63.6%) 22 (75.9%) 4 (66.7%) 25 (40.3%) 7 (70%) 183 (59%) 45 (45%)*
Age at visit 9.7 (6–11.5) 9.8 (6.5–14.7) 13.5 (10.3–
15.6)
15.9 (13.1–
17.8)
16 (12.9–
17.8)
15.5 (12.8–
17.5)
12.1 (6.1–14) 13.3 
(9.4–16.1)#
10.5 (8.3–
14.5)*
Age at onset 4.1 (2.7–5.6) 5.2 (3.4–8.8) 9.3 (5.9–12.9) 11.3 
(8.3–13.8)
13.2 (8.4–15) 11.7 (8–14.2) 3.2 (1.2–9.9) 8.3 (4.4–12.3)#
Disease duration 3.8 (2.6–6.9) 2.6 (0.9–6) 3 (1.3–5.4) 3.9 (2.6–6.8) 4.1 (2.8–4.6) 3.5 (1.7–6.1) 4.5 (1.2–8.6) 3.3 (1.3–6)
ESR 14 (8–32.5) 10 (6–19.5) 14 (8–26) 22 (12–31) 7 (6–15) 17 (8–35) 8 (7–45) 14 (8–28.5)*
MD VAS 0 (0–3) 1 (0–4) 2.5 (0–5) 3 (0–7) 0 (0–4) 2 (0–5) 1 (1–2) 2 (0–5)
No. swollen joints 0 (0–1) 1 (0–1) 0 (0–5) 0 (0–9) 9.5 (0–28) 0 (0–3) 0 (0–2) 0 (0–2)
No. joints with 
pain
0 (0–4) 1 (0–2) 2 (0–10) 10 (1–22) 24.5 (0–45) 4 (0–25) 2 (0–3) 2 (0–9)#
No. joints with 
LOM
0 (0–3) 0 (0–1) 1 (0–6) 1 (0–13) 0.5 (0–1) 1 (0–7) 1.5 (0–4) 0 (0–5)
No. active joints 0 (0–3) 1 (0–1) 2 (0–8) 1 (0–14) 14 (0–29) 1 (0–16) 0.5 (0–2) 1 (0–6)
Active systemic 
features
9 (24.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (10%) 10/307 
(3.3%)**
ANA status 2 (5.4%) 5 (7.5%) 7 (7.1%) 0 (0%) 0 (0%) 1 (1.6%) 0 (0%) 15 (4.8%)
Uveitis 0 (0%) 12/65 (18.5%) 11 (11.1%) 2 (6.9%) 0 (0%) 20/61 (32.8%) 3 (30%) 48/305 
(15.7%)**
PF total score 1 (0–5) 1 (0–3) 2 (0–9) 5 (0–10) 4 (2–8) 2.5 (0–10) 6.5 (0–16) 2 (0–8)* 0 (0–0)#
Pain VAS 0.5 (0–2.5) 1 (0–3.5) 2 (0–5) 3.8 (1.3–6) 5 (3–7) 4 (0.5–6) 1.5 (0–3.5) 1.8 (0–5)* 0 (0–0)#
Disease activity 
VAS
0 (0–3) 1 (0–3.5) 2 (0–4.5) 3 (0.5–5.5) 2.5 (1–7) 3.5 (0.5–5.5) 2.3 (0–8) 1.5 (0–5)
Well-being VAS 0 (0–2.5) 1 (0–4.5) 2 (0–4.5) 3.5 (1–6) 3 (0–6) 3 (0.5–6) 1 (0–8) 1.5 (0–5)*
HRQoL PhH 1 (0–4) 2 (1–4) 2.5 (1–7) 3 (2–7) 5 (4–6) 4 (2–8) 6 (1–10) 3 (1–6)* 0 (0–1)#
HRQoL PsH 2 (0–5) 2 (0–4) 2 (1–5) 4 (1–5) 2 (1–4) 3 (0–7) 2 (0–5) 2 (1–5) 3 (2–4)
HRQoL total 
score
4 (1–10) 4 (1–8) 5 (2–13) 7 (4–15) 6 (6–10) 6.5 (2–16) 10 (1–16) 5 (2–12) 3 (2–5)#
Pain/swell. in > 1 
joint
15/35 (42.9%) 40 (59.7%) 57/94 (60.6%) 18/25 (72%) 4/5 (80%) 36/54 (66.7%) 5 (50%) 175/290 
(60.3%)
0 (0%)#
Morning stiff-
ness > 15 min
4/34 (11.8%) 10 (14.9%) 18/94 (19.1%) 11/25 (44%) 3/5 (60%) 19/53 (35.8%) 3 (30%) 68/288 
(23.6%)**
0 (0%)#
Subjective remis-
sion
11/34 (32.4%) 37 (55.2%) 58/94 (61.7%) 17/24 (70.8%) 3/5 (60%) 37/53 (69.8%) 5 (50%) 168/287 
(58.5%)*
In treatment 27/35 (77.1%) 49/66 (74.2%) 88/94 (93.6%) 23/25 (92%) 5/5 (100%) 50/54 (92.6%) 10 (100%) 252/289 
(87.2%)*
Reporting side 
effects
8/27 (29.6%) 18/48 (37.5%) 26/87 (29.9%) 7/22 (31.8%) 4/5 (80%) 15/50 (30%) 2/9 (22.2%) 80/248 
(32.3%)
Taking medication 
regularly
26/27 (96.3%) 46/48 (95.8%) 80/85 (94.1%) 22/22 (100%) 5/5 (100%) 47/50 (94%) 8 (80%) 234/247 
(94.7%)
With problems 
attending school
1/19 (5.3%) 2/39 (5.1%) 8/57 (14%) 6/20 (30%) 0 (0%) 11/37 (29.7%) 2/5 (40%) 30/181 
(16.6%)**
0 (0%)#
Satisfied with dis-
ease outcome
27/35 (77.1%) 34/65 (52.3%) 51/93 (54.8%) 9/25 (36%) 1/5 (20%) 25/54 (46.3%) 7 (70%) 154/287 
(53.7%)*
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Equal item–scale correlations (second Likert 
assumption)
Pearson’s item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 100% of the 
PF items and for 100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson’s items–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 290/390) Child (N = 265/364)
Missing values (1st–3rd quartiles) 0.7 (0–2.8) 0.8 (0–2.3)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 78.3% 78.5%
 HRQoL PhH 52.1% 54%
 HRQoL PsH 48.6% 47.2%
 Pain VAS 30% 29.8%
 Disease activity VAS 30.3% 29.1%
 Well-being VAS 29% 29.1%
Ceiling effect, median
 PF 1% 0.8%
 HRQoL PhH 10.3% 9.4%
 HRQoL PsH 5.2% 4.5%
 Pain VAS 2.1% 1.5%
 Disease activity VAS 1% 1.5%
 Well-being VAS 1.4% 1.1%
Items with equivalent item–scale correlation 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Items with item–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.92 0.92
 PF-HW 0.93 0.93
 PF-US 0.85 0.85
 HRQoL-PhH 0.90 0.91
 HRQoL-PsH 0.86 0.90
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.74 0.97
 HRQoL-PhH 0.71 0.78
 HRQoL-PsH 1.0 0.92
Spearman’s correlation with JIA core set variables, median
 PF 0.6 0.7
 HRQoL PhH 0.7 0.7
 HRQoL PsH 0.5 0.5
 Pain VAS 0.5 0.6
 Disease activity VAS 0.5 0.6
 Well-being VAS 0.5 0.6
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.92 for PF-LL, 0.93 for PF-HW, 0.85 
for PF-US. Cronbach’s alpha was 0.90 for HRQoL-PhH and 
0.86 for HRQoL-PsH.
Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 16 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 7 days (0–20 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed 
a substantial reproducibility (ICC 0.74). The ICC for the 
HRQoL-PhH showed a substantial reproducibility (ICC 
0.71), while the ICC for the HRQoL-PsH showed an 
almost perfect reproducibility (ICC 1.0).
Convergent validity
The Spearman’s correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.4 
to 0.7 (median 0.6). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.4 to 0.8 (median 0.7), whereas for the PsH ranged 
from 0.3 to 0.6 (median 0.5). The PhH and the PsH showed 
the best correlation with the parent global assessment 
of well-being (r = 0.8, p < 0.001 and r = 0.6, p < 0.001, 
respectively). The median correlations between the pain 
VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 
0.5 (0.3–0.8), 0.5 (0.4–0.8), 0.5 (0.3–0.8), respectively.
Discussion
In this study, the Romanian version of the JAMAR was 
cross-culturally adapted from the original standard English 
version with two forward and two backward translations. 
According to the results of the validation analysis, the 
Romanian parent and patient versions of the JAMAR pos-
sess satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. Notably, 
there was no significant difference between the healthy 
subjects and their affected peers in the psychosocial qual-
ity of life variable. This finding indicates that children 
with JIA adapt well to the consequences of JIA. The PF 
total score proved to discriminate between the different 
JIA subtypes with children with undifferentiated arthritis 
having a higher degree of disability.
Psychometric performances were good for all domains 
of the JAMAR and the overall internal consistency was 
excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Romanian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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